Microbial-derived Carbohydrate-based Glycomedicine Development

Microbial-derived Carbohydrate-based Glycomedicine Development

Microorganisms responsible for infection (various bacteria, viruses, protozoan, etc.) often have carbohydrates different from those seen in humans. For this reason, it will be possible to prevent the onset of associated diseases by using drugs targeted at these particular carbohydrates. Microbial-derived polysaccharides commonly found in nature (starch, cellulose, mannan, xylan, gum, etc.) are playing an important role in the pharmaceutical field. CD BioGlyco offers customized services for microbial-derived carbohydrate-based glycomedicine development.

Effects of Polysaccharides and Glycoconjugates From Microorganisms

Carbohydrate-based vaccines constitute one of the most representative examples of the promise of glycomedicine in clinically relevant applications. Cell-surface polysaccharides and glycoconjugates from microorganisms such as bacteria, viruses, etc., have served as valuable antigenic targets for vaccine development, and have been widely used in the clinic against a range of infectious diseases, including meningitis, pneumonia, and influenza.

Moreover, structural and pharmacological studies revealed that fungal glycans show multiple physiological and healthy promoting effects including immunomodulation, anti-tumor, anti-aging, anti-oxidation, hypoglycemic, hypolipidemic, anti-radiation, and other effects. Understanding the fungal glycan-based drugs at the molecular biological level would be needed to comprehend the clinical efficacy of glycan-based drugs.

Modified dextrans.Fig.1 Modified dextrans. (Dheer, et al., 2017)

Microbial-derived Carbohydrate-based Glycomedicine Development Services

CD BioGlyco provides a comprehensive service for microbial-derived natural polysaccharides, such as dextran and xanthan gum. Our service includes isolation, purification, biological activity identification, and structural identification of microbial-derived natural polysaccharides. In addition, CD BioGlyco has developed a variety of strategies for microbial-derived carbohydrate-based glycomedicine development. For example, the design of targeted block copolymers containing microbial-derived carbohydrates.


  • Targeting specific and long-acting delivery.
  • Development of anticancer drugs.
  • Development of microbial-derived carbohydrate-based drug delivery systems for sustained drug release.

Advantages of Us

  • Precise targeting.
  • Various modifications can be customized
  • A variety of strategies

CD BioGlyco has experienced scientists and the most advanced carbohydrate-based glycomedicine development platform, which provides customers with customized services in the development of microbial-derived carbohydrate glycomedicine. If you are interested in our services, please contact us for more details without any hesitation.


  1. Dheer, D.; et al. Polysaccharides based nanomaterials for targeted anti-cancer drug delivery. Journal of drug targeting. 2017, 25(1): 1-16.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.